Virbac SA
PAR:VIRP
Virbac SA
Operating Expenses
Virbac SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Virbac SA
PAR:VIRP
|
Operating Expenses
-€719m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-11%
|
|
|
Sanofi SA
PAR:SAN
|
Operating Expenses
-€21.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Ipsen SA
PAR:IPN
|
Operating Expenses
-€2.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
|
Vetoquinol SA
PAR:VETO
|
Operating Expenses
-€197.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Boiron SA
PAR:BOI
|
Operating Expenses
-€321.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Medincell SA
PAR:MEDCL
|
Operating Expenses
-€29.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Virbac SA
Glance View
Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.
See Also
What is Virbac SA's Operating Expenses?
Operating Expenses
-719m
EUR
Based on the financial report for Dec 31, 2024, Virbac SA's Operating Expenses amounts to -719m EUR.
What is Virbac SA's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-11%
Over the last year, the Operating Expenses growth was -15%. The average annual Operating Expenses growth rates for Virbac SA have been -29% over the past three years , -15% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet